Results 61 to 70 of about 16,438 (200)

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Enhancement within the orbits and superficial temporal artery: MRI clues to the diagnosis of giant cell arteritis

American Journal of Ophthalmology Case Reports
Purpose: Giant cell arteritis can have protean manifestations, many of them non-specific. We describe a patient whose initial presentation was most consistent with brainstem stroke, but who was ultimately diagnosed with and treated for giant cell ...
George Sanchez, Theresa M. Long, Judith E.A. Warner, Lee S. Chung, Edward Patrick Quigley, III, Kathleen B. Digre, Meagan D. Seay, Alison V. Crum, Bradley J. Katz   +8 more
doaj   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Fatal Aortic Dissection in a Patient with Giant Cell Arteritis: A Case Report and Review of the Literature

Case Reports in Vascular Medicine, 2013
Giant cell arteritis may lead to catastrophic, large-vessel complications from chronic vascular wall inflammation without prompt diagnosis and treatment.
Anjeli K. Nayar, Michael Casciello, Jennifer N. Slim, Ahmad M. Slim   +3 more
doaj   +1 more source

Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study evaluates antinuclear antibody (ANA) test performance in identifying rheumatologic conditions as the source of the headache. Background ANA testing is widely used to screen for autoimmune diseases in patients with headaches, but its diagnostic utility remains unclear. Methods In this retrospective analytic, cross‐sectional
Erez Magiel, Melanie Shanie Roitman, Barak Pflantzer, Roni Loebenstein Dagan, Roni Sharon, Abdualla Watad, Nicola Maggio, Saar Anis   +7 more
wiley   +1 more source

Experience of Australian rheumatologists managing polymyalgia rheumatica: results from a national survey

Internal Medicine Journal, EarlyView.
Abstract Background Polymyalgia rheumatica is the commonest inflammatory condition affecting adults over 50 years of age, however it has been under‐researched and management varies in everyday clinical practice. Aim This national survey of rheumatologists and trainees managing polymyalgia rheumatica (PMR) in Australia sought to determine current ...
Jessica L. Leung, Victor Yang, Jem V. Ninan, Carlee Ruediger, David F. L. Liew, Russell R. C. Buchanan, Helen I. Keen, Catherine L. Hill, Claire E. Owen   +8 more
wiley   +1 more source

Giant cell arteritis as a cause of fever of unclear genesis in the elderly

Терапевтический архив, 2014
The paper describes a case of giant cell arteritis whose leading clinical sign is long-term fever. It discusses current approaches to diagnosing giant cell arteritis.
S V Guliaev, A D Meshkov, P I Novikov, S V Moiseev, V V Fomin   +4 more
doaj  

Tocilizumab for severe and refractory mucous membrane pemphigoid

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt, Maud Maho‐Vaillant, Julie Gueudry, Marie‐Laure Golinski, Marion Marcaillou, Blanche Bergeret, Guillaume Chambon, Pierre Bouchetemble, Soumeya Bekri, Abdellah Tebani, Hervé Maillard, Cécile Morice, Anais Vautier, Edgar‐Pierre Libert, Christelle Le Roux‐Villet, Marion Carrette, Olivier Boyer, Vivien Hébert, Sébastien Calbo, André Gillibert, Pascal Joly   +20 more
wiley   +1 more source

Aortitis in Extracranial Giant Cell Arteritis: Do Not Lose Sight of the Patient

Annals of Internal Medicine: Clinical Cases
Giant cell arteritis is the most common systemic vasculitis. This case highlights aortic dissection as a potentially life-threatening complication of giant cell arteritis, in most instances occurring as very late event years or even decades after initial
Lilly J.U. Reik, Maximilian A. Pichlmaier, Nikolaous Tsilimparis, Michael Czihal   +3 more
doaj   +1 more source